Levomilnacipran
Records for this ingredient, by country (identity only).
ATC N06AX28 · 4 markets · 15 records
CA 8 records · 4 shown of 4
- 80 mgcapsule · extended-releaseAPO-LEVOMILNACIPRANFetzima
- 40 mgcapsule · extended-releaseAPO-LEVOMILNACIPRANFetzima
- 120 mgcapsule · extended-releaseAPO-LEVOMILNACIPRANFetzima
- 20 mgcapsule · extended-releaseAPO-LEVOMILNACIPRANFetzima
US 4 records · 4 shown of 4
GB 2 records · 2 shown of 2
- 80 mgcapsule · extended-releaseFetzima 40mg modified-release capsules
- 40 mgcapsule · extended-releaseFetzima 40mg modified-release capsules
| Strength / form / release | US | GB | CA |
|---|---|---|---|
| 80 mg capsule · extended-release | Fetzima | Fetzima 40mg modified-release capsules | APO-LEVOMILNACIPRAN Fetzima |
| 40 mg capsule · extended-release | Fetzima | Fetzima 40mg modified-release capsules | APO-LEVOMILNACIPRAN Fetzima |
| 120 mg capsule · extended-release | Fetzima | APO-LEVOMILNACIPRAN Fetzima | |
| 20 mg capsule · extended-release | Fetzima | APO-LEVOMILNACIPRAN Fetzima |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
The same ingredient can carry completely different
brand names in different countries, and the same name can point to a different ingredient.
Listed by country — not interchangeable.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.